Kathryn Hanks
Surgical · Fresno, CANPI 1558739052
Payments from drug & device makers
Across 127 payments — averaging $28.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$875
- AbbVie$375
- Bayer$355
- Novo Nordisk$277
- Novartis$223
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$172
- plus $1K from 17 others
What the payments were for
- Food & beverage$3,59299%
- Education$231%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 34 | $875 |
| AbbVie | 3 | $375 |
| Bayer | 12 | $355 |
| Novo Nordisk | 4 | $277 |
| Novartis | 13 | $223 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $172 |
| Abbott | 3 | $157 |
| Kiniksa Pharmaceuticals, Ltd. | 3 | $155 |
| Neurocrine Biosciences, Inc. | 1 | $140 |
| Medtronic | 5 | $137 |
| Boehringer Ingelheim | 7 | $119 |
| Amarin Pharma, Inc. | 6 | $115 |
| Neurelis, Inc. | 1 | $95 |
| Esperion Therapeutics, Inc. | 6 | $87 |
| Pfizer | 4 | $76 |
| Cvrx, Inc. | 7 | $66 |
| Biotronik Inc. | 2 | $51 |
| Actelion Pharmaceuticals US, Inc. | 2 | $43 |
| Integra Lifesciences Corporation | 1 | $29 |
| Arbor Pharmaceuticals, Inc. | 1 | $22 |
| Merck | 1 | $19 |
| AstraZeneca | 1 | $16 |
| Johnson & Johnson | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,615 in reported general payments places this provider in the 85th percentile of 729 surgical providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 22 | $33,634 |
| Repatha SureclickEvolocumab | 32 | $18,811 |
| Repatha SyringeEvolocumab | 15 | $12,888 |
| XareltoRivaroxaban | 11 | $11,024 |
| EntrestoSacubitril/Valsartan | 11 | $8,223 |
| Praluent PenAlirocumab | 12 | $5,726 |
| Telmisartan | 58 | $2,355 |
| Atorvastatin Calcium | 152 | $2,214 |
| Olmesartan Medoxomil | 11 | $1,177 |
| Ezetimibe | 44 | $875 |
| Metoprolol Succinate | 37 | $809 |
| Carvedilol | 51 | $496 |
| Lisinopril | 45 | $420 |
| SotalolSotalol Hcl | 12 | $407 |
| Amlodipine Besylate | 37 | $353 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $76 | $33,63422 claims |
| Johnson & JohnsonXarelto | $14 | $11,02411 claims |
| NovartisEntresto | $223 | $8,22311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 729 surgical providers in California.
Other surgical in Fresno
- Naira AsatrianFresno$10K
- Tuantu Doan VuFresno$6K
- Brittany CoxFresno$5K
- Lauren AmicoVista$989K
- Cheyanne MallasWest Hollywood$199K
- Laura PietrzakMarina del Rey$63K
- Jane HartiganSanta Rosa$27K
- Kenny NgoPalo Alto$25K
- Crispin MarRancho Santa Margarita$23K
- Robert FrostRancho Santa Margarita$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.